Compare Neurocrine Biosciences Inc (NBIX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs 22nd Century Group Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Neurocrine Biosciences Inc is far larger — about 11677.9× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| NBIX | XXII | |
|---|---|---|
Market Cap | $17.40B | $1.49M |
Sector | Health | Technology |
52-Week High | $180.55 | $1.07K |
52-Week Low | $123.10 | $3.90 |
Enterprise Value | $16.49B | -$6.74M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
